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Aims Long-term results from catheter ablation therapy for atrial fibrillation (AF) remain uncertain and clinical practice
guidelines recommend continuation of long-term oral anticoagulation in patients with a high stroke risk. Left atrial
appendage closure (LAAC) with Watchman has emerged as an alternative to long-term anticoagulation for patients
accepting of the procedural risks. We report on the initial results of combining catheter ablation procedures for
AF and LAAC in a multicentre registry.
...................................................................................................................................................................................................
Methods and
results
Data were pooled from two prospective, real-world Watchman LAAC registries running in parallel in Europe/
Middle-East/Russia (EWOLUTION) and Asia/Australia (WASP) between 2013 and 2015. Of the 1140 patients, 139
subjects at 10 centres underwent a concomitant AF ablation and LAAC procedure. The mean CHA2DS2-VASc
score was 3.4 ± 1.4 and HAS-BLED score 1.5 ± 0.9. Successful Watchman implantation was achieved in 100% of pa-
tients. The overall 30-day serious adverse event (SAE) rate was 8.7%, with the device and/or procedure-related
SAE rate of 1.4%. One pericardial effusion required percutaneous drainage, but there were no strokes, device em-
bolization, or deaths at 30 days. The 30-day bleeding SAE rate was 2.9% with 55% of patients prescribed NOAC
and 38% taking warfarin post-procedure.
...................................................................................................................................................................................................
Conclusion The outcomes from these international, multicentre registries support the feasibility and safety of performing com-
bined procedures of ablation and Watchman LAAC for patients with non-valvular AF and high stroke risk. Further
data are needed on long-term outcomes for the hybrid technique on all-cause stroke and mortality.
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Introduction
Long-term results from catheter ablation therapy for atrial fibrillation
(AF) remain uncertain with significant rates of arrhythmia recurrence
over time, especially in the persistent AF population.1
The CHA2DS2-VASc risk score has been demonstrated to correlate
with both risk of AF recurrence and risk of thromboembolic events
post-ablation,2,3 suggesting a need for on-going stroke protection in
high risk patients. As a result, clinical practice guidelines recommend
continuation of long-term oral anticoagulation in these patients fol-
lowing catheter ablation therapy.4
Left atrial appendage (LAA) occlusion has emerged as an alterna-
tive to long-term anticoagulation with warfarin with similar demon-
strated efficacy for all- cause stroke prevention.5,6 Patients with non-
valvular AF who elect to undergo catheter ablation therapy (and are
therefore accepting of the procedural risks) may consider this non-
pharmacologic approach for long-term stroke prevention. It has been
suggested that combining the two left atrial interventions may be a
valuable and practical approach because of the common aspects of
transseptal puncture, general anaesthesia and requirement for post-
procedural anticoagulation.7 We report on the feasibility and safety
of combining catheter ablation procedures for AF and left atrial ap-
pendage closure (LAAC) in prospective international multicentre
registries.
Methods
This study was approved by the respective institutional review boards for
human research and complies with the Declaration of Helsinki. Informed
consent was obtained from all those participating in either the prospect-
ive, multicentre EWOLUTION8 or WASP registries. Both trials were
registered on ClinicalTrials.gov (NCT01972282 and NCT01972295, re-
spectively). The trials were designed to collect real-world usage and out-
comes data for patients implanted with the Watchman LAAC device
(Boston Scientific Corporation; Natick, MA). Both registries had identical
inclusion/exclusion criteria, used appropriate guidelines to determine de-
vice eligibility, and were performed by trained implanters. A contract re-
search organization monitored both studies, and conducted at least one
centre visit to verify accuracy and completeness of 30-day follow-up data.
Procedural planning
Pre-procedural transoesophageal echocardiogram (TOE) was generally
advised to exclude LAA thrombus and to assess suitability of the ostial di-
mensions of the appendage.5
Procedure
Procedures were performed according to the device’s Directions for
Use, and periprocedural oral anticoagulation, pre-ablation intravenous
(IV) heparin, and target activated clotting time (ACT) were managed at
the Physician’s discretion.
Per Physician discretion, ablation energy modality, use of cardiac navi-
gational system and ancillary catheters to guide electrophysiological map-
ping and ablation was individualized. The ablation endpoint was left and
right-sided pulmonary vein electrical isolation, as well as any additional
left or right atrial ablation deemed necessary by the operator. The major-
ity of operators reported performing a deliberately more posterior ap-
proach transseptal puncture for the ablation catheter that was
subsequently exchanged for the Watchman access sheath. One centre
reported using intracardiac echocardiography during the ablation phase
of the procedure, however, all centres reported use of TOE to guide
LAA device closure. After completion of the ablation phase a mean left
atrial pressure measurement of >_10 mmHg was obtained, and the LAA
was assessed using TOE imaging at angles of approximately 0, 45 , 90,
and 135. Implant of the LAA closure device was then performed as pre-
viously described.5 Post-procedural oral anticoagulation was at the
Physician’s discretion.
Patient follow-up
Follow-up TOE imaging was recommended at 6 weeks to reassess device
position and any residual jet flow around the device. If satisfactory appear-
ances on TOE follow-up study had been confirmed, oral anticoagulation
discontinuation was recommended and patients were then recom-
mended for antiplatelet therapy (aspirin 81–325 mgþ clopidogrel 75 mg)
for 6 months post-implant or at the discretion of the Physician. Left atrial
appendage occlusion was defined as satisfactory positioning of the device
at the ostium covering all trabeculated portions of the LAA with peri-
device flow <_5 mm.5,7 The schedule of clinical follow-up of patients was
at the discretion of the Physician.
Both trials required serious adverse events (SAEs) reporting per ISO
14155 and the MEDDEV 2.7/3 12/2010. Adjudication was performed by
investigators with oversight by a Medical Safety Group, as previously
described.8 Events included procedure-related complications (e.g. serious
pericardial effusion, device embolization, and procedure-related stroke)
and events related to excessive bleeding (e.g. intracranial or gastrointes-
tinal bleeding) scored according to the Bleeding Academic Research
Consortium (BARC) criteria.9 Safety events were further classified as
Watchman procedure-related, device-related or related to prescribed
anticoagulation regimen. Efficacy endpoints also required reporting of any
occurrence of stroke (including ischaemic or haemorrhagic stroke),
death, or systemic embolism.
Statistical analysis
Continuous variables are summarized using the mean, standard deviation,
and range and categorical variables with counts and percentages. The
Kaplan–Meier method was used to describe adverse events.
Results
Patient demographics
Enrolment in the EWOLUTION study included 1025 patients and
spanned from October 2013 to May 2015 in 47 centres across
13 countries in Europe, the Middle East and Russia. Enrolment in the
WASP trial commenced in January 2014 and concluded in October
What’s new?
• This is the first international multicentre series to date demon-
strating the feasibility and safety of combined procedures of
catheter ablation for AF and left atrial appendage device
occlusion
• This multicentre experience points to similar complication
rates for the combined procedure as for catheter ablation
alone in the hands of experienced AF ablation operators
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2015, resulting in 201 patients across 7 countries including Australia,
Asia, and the Middle East.
Of the 1140 patients from both registries 139 subjects at
10 centres underwent a concomitant ablation and LAAC procedure
and are included in our analysis. The majority of cases (97%) were
performed by experienced AF catheter ablation proceduralists (>_50
procedures per year)10 and all implanters were trained, certified
implanters of the device.
The mean age at time of consent was 64.1 ± 7.3 years, and 54.7%
patients were male. Stroke risk scores (mean ± SD) for CHADS2 and
CHA2DS2-VASc were 2.2 ± 1.2 and 3.4 ± 1.4, respectively, whereas
the HAS-BLED score was 1.5 ± 0.9. Key characteristics contributing
to stroke risk scores were hypertension (81.3%), age of 65–74
(41.0%), and history of TIA/Stroke (41.0%), whereas many of the
same components also contributed to the HAS-BLED bleeding risk
scores [uncontrolled hypertension (15.8%), history of stroke
(29.5%), and age > 65 (41.0%)], as well as concomitant use of drugs
(30.2%). The primary AF pattern was paroxysmal in 68.3%. The indi-
cations for LAA device occlusion included labile INRs in 25 (17.9%),
requirement for concomitant drug therapy in 42 (30.2%), previous
major bleeding in 14 (10.0%), recurrent anaemia due to gastrointes-
tinal bleeding in 4 (2.8%), history of blood dyscrasia in 1 (0.7%), alco-
hol abuse in 8 (5.7%), senility in 1 (0.7%), job or lifestyle that prohibits
warfarin use in 28 (20.1%), other contraindication e.g. HAS-BLED
score >_ 3 in 20 (14.3%), and reason not recorded in 30 (21.5%). For a
complete listing of all demographics, see Table 1.
Procedural success
All procedures were successful and all implants achieved a satisfac-
tory seal (residual leak <_5 mm) per device release specifications pre-
viously described.5 The mean procedural time was 177 ± 44 min and
mean fluoroscopy time 31 ± 9 min. Complete occlusion was achieved
in 97.1% of the implants, while 2.9% of patients had a residual leak
<_5 mm. The majority of devices were released without recapture or
device resizing (71.9 and 97.1%, respectively). The mean LAA diam-
eter was 20.8 ± 2.8 mm, resulting in final device size of primarily 24 or
27 mm (34.5 and 29.5%, respectively) with an oversizing of 10–30%
for the majority of patients (80.6%) and a mean achieved device com-
pression of 14.0 ± 6.0 %. See Table 2 for additional information. The
ablation modality used by the different operators included irrigated
radiofrequency ablation in 105 patients, cryoballoon in 1 patient,
non-irrigated phased radiofrequency energy multielectrode applica-
tions in 29 patients and modality not recorded in 4 patients. Ablation
endpoints were not recorded in the registry dataset.
Oral anticoagulant regimen
Post-implant, 92.8% of patients were prescribed an oral anticoagulant
(54.7% novel oral anticoagulant (NOAC) 38.1% warfarin), 5.8% were
given anti-platelet (3.6% dual, 2.2% single), and the remainder
received no therapy (1.4%). Of the 76 patients prescribed a NOAC
post-procedure 40 were taking Dabigatran, 31 were on Rivaroxaban,
and 5 were prescribed Apixaban.
Adverse events
The 7-day device and/or procedure related SAE rate was 0.7% (0.1%,
3.6%). The overall 30-day SAE rate was 8.7% (4.7%, 14.1%) with
14 events in 12 patients, while the device and/or procedure-related
SAE rate was 1.4% (0.3%, 4.7%). There were four significant bleeding
events including progressive anaemia due to recurrent gastrointes-
tinal bleeding on NOAC (known gastric vascular ectasia) requiring
transfusion Day 1 post-procedure, frank haematuria on warfarin Day
5 post-procedure, secondary bleed from groin (vascular access) on
warfarin requiring transfusion on Day 13 post-procedure and trau-
matic knee haematoma on NOAC on Day 28 post-procedure. The
bleeding SAE rate at 30-days was 2.9% (0.9%, 6.7%) (Figure 1). One
..................................................................................................
Table 1 Baseline Characteristics
Characteristics Summary statistics
Age at time of consent (years)
Mean ± SD 64.1 ± 7.3
Range (39.0, 85.0)
Age >_80 0.7% (1/139)
Male 54.7% (76/139)
CHADS2 Score—continuous
Mean ± SD 2.2 ± 1.2
Range (0.00, 5.00)
CHA2DS2-VASc Score—continuous
Mean ± SD 3.4 ± 1.4
Range (0.00, 7.00)
HAS-BLED Score—continuous
Mean ± SD 1.5 ± 0.9
Range (0.00, 4.00)
Components of CHADS2 and CHA2DS2-VASc Scores
CHF 34.5% (48/139)
Hypertension 81.3% (113/139)
Age >_75 9.4% (13/139)
Age 65–74 41.0% (57/139)
Diabetes 13.7% (19/139)
History of TIA/stroke 41.0% (57/139)
Vascular disease 20.9% (29/139)
Female 45.3% (63/139)
Components of HAS-BLED Scores
Uncontrolled hypertension 15.8% (22/139)
Abnormal renal function 2.2% (3/139)
Abnormal liver function 0.0% (0/139)
History of ischaemic/haemorrhagic stroke 29.5% (41/139)
Prior major bleeding or
predisposition to bleeding
5.0% (7/139)
Labile INRs 18.0% (25/139)
Concomitant use of drugs 30.2% (42/139)
Alcohol abuse 5.8% (8/139)
Age >65 41.0% (57/139)
AF pattern
Paroxysmal 68.3% (95/139)
Persistent 28.8% (40/139)
Long-standing persistent 1.4% (2/139)
Values presented are % (N/total) or mean ± standard deviation, range (minimum,
maximum).
CHF, congestive heart failure; TIA, transient ischaemic attack; INRs, international
normalized ratios; AF, atrial fibrillation; SD, standard deviation.
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pericardial effusion with tamponade occurred on day 12 post-
procedure, which resolved with pericardiocentesis; another patient
was noted to have an increase in size of pre-existing pericardial effu-
sion on the day of the procedure but did not require intervention.
There were no strokes, TIAs, device embolization or deaths over the
initial follow-up for this cohort (Table 3).
Transoesophageal echocardiogram
follow-up
A first follow-up TOE was performed at least 28 days post-proced-
ure in 105/139 patients and demonstrated proper seal (residual leak
<_5 mm) in almost all of the patients studied (98.1%). Two patients
had a jet size >5 mm determined to be due to device migration and
were continued on OAC. The complete LAA occlusion rate was
noted to decline to 61.0% at initial TOE follow-up. Comparison be-
tween achieved device compression for patients with a new or per-
sisting peri-device leak at TOE follow-up and patients with complete
occlusion maintained showed no statistically significant difference
(14.0 ± 6.0% vs. 16.0 ± 6.0%, P= 0.15). Comparisons could not be
made based on ablation modality due to only one centre performing
cryoablation, leading to insufficient numbers for analysis. Device
associated thrombus was detected on follow-up TOE in 3 patients
(2.1%) resolving without clinical sequelae on continued oral
anticoagulation.
Discussion
This report represents the largest patient series to date and supports
the feasibility of combining catheter ablation and Watchman LAA de-
vice closure procedures. The results replicate other single-centre
series11–14 but are now supported by two large international, multi-
centre registry experiences. The results support the EHRA/EAPCI
expert consensus statement on catheter based LAA Occlusion7 that
proposed the combination procedure ‘seems to be a valuable and
practical approach: patients with a significant risk of thrombo-
embolic events (CHA2DS2-VASc score of >2) undergoing an ablation
procedure to treat symptomatic AF, who, in addition, have a strict or
relative contraindication to (N)OACs.’
The results are remarkable for excellent documented peri-
procedural safety. In the hands of experienced AF ablation operators
the pericardial effusion rate was 1.4%, pericardial tamponade rate
requiring intervention 0.7%, with no periprocedural strokes or
procedure-related deaths. The results are superior to previous
Watchman trials5,15 and remain consistent with the wider context of
already published EWOLUTION registry results which demon-
strated that contemporary implant techniques are achieving low peri-
procedural risk even in higher risk patient groups.8 Indeed, the results
of this substudy also compare favourably even to reported complica-
tion rates from catheter ablation alone in previous worldwide AF ab-
lation surveys.16 The results suggest that, for high volume operators,
the addition of LAA occlusion to an ablation procedure for AF does
not increase the chance of major complications.
While the experience with LAAC implant technique continues to
evolve, the results are also notable for 100% device implant success
by the operators. This compares with 91% implant success in
PROTECT AF,5 95% in PREVAIL trials,15 and 98.5% in the overall
EWOLUTION registry.8 Very high rates of optimal device placement
were also achieved with a small peri-device leak in only 2.9% of im-
plants and minimal procedural device repositioning required.
However, the new occurrence of small peri-device leaks at first
TOE follow-up requires further consideration. The rate of peri-
device leaks increased significantly from 2.9% at implant to 39% at
first follow-up (in the 105/139 patients studied). In two patients, this
resulted in a leak >5 mm rendering a result of incomplete LAA occlu-
sion at early follow-up, although the latter cases were determined to
be due to device migration. The phenomenon of new peri-device
leaks has been noted in other single-centre series of LAAC implant17
as well as combined ablation with LAAC procedures.11,12 Upon sub-
sequent follow-up in the two series employing the combined proced-
ure, the majority of leaks resolved or reduced in size.11,12 PROTECT
AF documented a 40.9% peri-device leak rate at 45 days follow-up18
but also documented a reduction in leak rate to 32.1% over the first
12 months. The proposed explanations for the new occurrence of a
post-implant peri-device leak have included a mismatch between cir-
cular device and non-circular LAA orifice, the effect of oedema at im-
plant masking any mismatch in device size, and the potential for atrial
remodelling to increase or decrease any leak over time.11,17 The
.................................................................................................
Table 2 Procedural results
Procedure Summary statistics
Successful implant 100.0% (139)
LAA Seal—implant
Complete seal 97.1% (135/139)
Jet Size <_5 mm 2.9% (4/139)
Jet Size >5 mm 0.0% (0/139)
LAA Seal >28 days post-implant
Complete seal 61.0% (64/105)
Jet size <_5 mm 37.1% (39/105)
Jet size >5 mm 1.9% (2/105)
Number of recaptures
0 71.9% (100/139)
1–2 18.7% (26/139)
>_3 9.4% (13/139)
Number of device size changes per implant—categorical
0 97.1% (135/139)
1 2.9% (4/139)
2 0.0% (0/139)
LAA diameter
Mean ± SD 20.8 ± 2.8
Range (14.0, 28.0)
Device compression
Mean ± SD 14.0% ± 6.0%
Device oversizing
<10% 8.6% (12/139)
10–30% 80.6% (112/139)
>30% 10.8% (15/139)
Values presented are % (N/total) or mean ± SD, range (minimum, maximum).
mm, millimetres; LAA, left atrial appendage; SD, standard deviation.
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degree of device oversizing at implant may also affect the long-term
seal in the face of any remodelling forces. A previous series has dem-
onstrated that persistent peri-device leaks at follow-up were more
likely to be associated with lower achieved device compression
(12 ± 3%) than implants achieving complete occlusion (15 ± 5%).11 In
the current study device compression was 14 ± 6% in patients with
new or persistent leaks and 16 ± 6% in patients with complete occlu-
sion at follow-up, however, the difference did not achieve statistical
significance. Further analysis of the impact of recommended device
oversizing on long-term complete occlusion rates is required.
....................................................................................................................................................................................................................
Table 3 Kaplan–Meier rates for serious adverse events at 30-days post-implant
Serious adverse event—30 days* Number of events Kaplan–Meier event rate
Pericardial effusions requiring intervention/cardiac tamponade 1 0.7%
Pericardial effusions not requiring intervention 2 1.4%
Coronary air embolism 1 0.7%
Bleeding (GI, haematuria, groin, knee haematoma) 4 2.9%
Urinary tract infection 1 0.7%
Pneumonia following traumatic knee haematoma 1 0.7%
Renal insufficiency following traumatic knee haematoma 1 0.7%
Right atrial flutter requiring ablation 1 0.7%
Recurrent atrial fibrillation requiring hospitalization 1 0.7%
Hypotension due to adverse drug reaction 1 0.7%
Device embolization 0 0%
Stroke 0 0%
Death 0 0%
GI, gastrointestinal.
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Figure 1 Kaplan–Meier curves and rates at zero (0), 1, 7, and 30 days post-implant for (A) all serious adverse events and (B) all bleeding serious ad-
verse events.
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Fortunately the clinical significance of small peri-device leaks has re-
mained questionable as no association has been proven with subse-
quent stroke or thromboembolic events.18
Systemic anticoagulation is routinely recommended for a minimum
of 2 months following catheter ablation for AF.19 Increasingly, phys-
icians are utilizing NOACs in place of warfarin as periprocedural anti-
coagulation for AF catheter ablation.20 However, there has been
limited experience to-date using the newer agents as a replacement
for short-term warfarin for Watchman LAA closure. NOACs were
used post-procedure in 55% of patients in this cohort, with no re-
corded cases of device-related thrombus. This international, multi-
centre experience now adds to the experience with the use of
NOACs with the LAAC implant procedure11 and suggests they are
compatible with the prosthetic material. Further the 30-day bleeding
SAE rate of 2.9% for the cohort (with events equally distributed be-
tween NOAC and warfarin use) is also consistent with contempor-
ary results from catheter ablation alone.20
The results from the EWOLUTION registry demonstrated a stat-
istically significant higher rate of SAE at 30 days for patients ‘eligible
for (and prescribed) oral anticoagulation treatment’ than patients ‘in-
eligible for oral anticoagulation treatment’ (and hence prescribed ei-
ther antiplatelet or no therapy) (6.5% vs. 10.2%, P= 0.042).8 In the
current substudy, the 30-day SAE rate was 8.7% for this particular
group of predominantly anticoagulated patients. Further compari-
sons, however, are limited by significant differences in baseline char-
acteristics of predominantly younger patients with lower risk scores
than the general EWOLUTION cohort,8 plus the added complexity
of the combined procedure.
Study limitations and future directions
Multiple limitations arise from a real-world registry design including
non-conformity of treatment (e.g. variation in ablation modality,
post-discharge anticoagulation regimen) and non-conformity of
follow-up (e.g. incomplete TOE follow-up). Further, because the
registry dataset was primarily focused on device results data was not
prospectively collected on arrhythmia outcomes for the cohort.
Additionally since no Corelab or independent image adjudication was
employed in either study, all TOE measurements (LAA diameter, de-
vice size, compression, and peri-device leak) are subject to operator
interpretation and imaging system variability.
The authors acknowledge that the lack of arrhythmia outcomes is
a major drawback of the current report. A previous small random-
ized trial suggested that combining Watchman LAA closure with
catheter ablation for AF had no effect on long-term AF recur-
rences.13 However larger randomized trials are needed to address
the relative risk-benefit of performing the procedures separately vs. a
combined approach and to specifically address any differences that
might arise from choice of ablation modality e.g. cryoballoon vs.
radiofrequency energy.
The authors also acknowledge that reimbursement considerations
in different regions around the world will tend to either drive or hin-
der the adoption of the combined approach.
Conclusion
The outcomes from this international, multicentre registry support
the feasibility and safety of performing combined procedures of
catheter ablation and Watchman LAA device implant for patients
with non-valvular AF and high stroke risk. Further data are needed on
the long-term outcomes for the hybrid technique on all-cause stroke
and mortality.
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Thoracoscopic left atrial appendage clipping as novel treatment option for
peri-device leakage
Athina M. Kougioumtzoglou1, Tim Smith1, Martin J. Swaans2, Lucas V.A. Boersma2, and Bart P. van Putte1,3*
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PO Box 2500, 3435 CM Nieuwegein, The Netherlands; and 3Department of Cardiothoracic Surgery, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam,
The Netherlands
* Corresponding author. Tel: 131 088 320 11 80; fax: 131 088 320 11 96. E-mail address: b.van.putte@antoniusziekenhuis.nl
A 69-year-old woman known with symptomatic antiarrhythmic
drug refractory paroxysmal atrial fibrillation (AF), stroke
(CHA2DS2-VASc score 5), and therapy-resistant epilepsy resulting
in collapses with risk for head trauma (HAS-BLED score 3), under-
went catheter ablation and transcatheter left atrial appendage (LAA)
occlusion (WATCHMANTM 24 mm, Boston Scientific, Natick, MA,
USA). Computed tomography (CT) scan revealed significant peri-
device leakage (4–5 mm). Due to the absolute contra-indication for
oral anticoagulation therapy, the patient was referred for thoraco-
scopic LAA-clipping (Atriclip PRO 145, AtriCure Inc., Dayton, OH,
USA). Additionally, a totally thoracoscopic MAZE procedure (TT-
MAZE) was performed. Perioperative Transesophageal echocar-
diography (TEE) showed complete closure of the LAA, which was
confirmed on CT-scan performed 2 months after surgery.
A 77-year-old male with a history of permanent AF (CHA2DS2-
VASc score 4), prostate carcinoma, and gastro-intestinal bleedings
(HAS-BLED score 3), underwent a WATCHMAN LAA occlusion
(24 mm). Computed tomography scan revealed significant peri-
device leakage (9 mm). The patient was referred for thoracoscopic
LAA-clipping (Atriclip PRO 150). Additionally, a TT-MAZE was per-
formed. Post-operative CT scan showed complete closure of the LAA as shown in Figure (the WATCHMAN (black arrow) and Atriclip
(white arrow) are both in situ with no contrast in the LAA).
Thoracoscopic LAA-clipping seems to be a feasible treatment option for peri-device leakage after incomplete transcatheter
LAA-closure.
The full-length version of this report can be viewed at: http://www.escardio.org/Guidelines-&-Education/E-learning/Clinical-cases/
Electrophysiology/EP-Case-Reports.
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